Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Combining xanomeline and trospium, Cobenfy selectively targets M1 and M4 receptors, rather than traditional dopamine ... Ebglyss (lebrikizumab) developed by Eli Lilly and Co and Almirall|atopic ...

Eli Lilly and Company (NYSE ... a refreshed low-cost iPad, and an M4 MacBook Air. The iPhone SE, the company’s first device with an Apple 5G modem, will see an update in 2025, and it is expected ...

Also covered by the pact is a dual M1/M4 agonist and a selective M1 agonist ... originally developed by Eli Lilly, that had been shelved because it was hard to tolerate. Karuna's solution is ...

ALIA-1758 is in the same general class as Eisai/Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab ... Finally, it is testing muscarinic M4 receptor-targeting candidate emraclidine ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Key Takeaways Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell ...

Eli Lilly (LLY) reports Q4 earnings Thursday. LLY stock up 8.22% YTD. Chart shows strong bullish momentum with potential for ...

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $732 billion, has been ...

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...